Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report)’s stock price traded down 3.3% during mid-day trading on Monday . The stock traded as low as $3.70 and last traded at $3.87. 178,113 shares traded hands during mid-day trading, a decline of 30% from the average session volume of 254,496 shares. The stock had previously closed at $4.00.
Relmada Therapeutics Price Performance
The stock has a market cap of $116.76 million, a P/E ratio of -1.18 and a beta of 0.19. The business’s 50 day simple moving average is $5.23 and its 200 day simple moving average is $3.98.
Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported ($0.84) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.04. Research analysts predict that Relmada Therapeutics, Inc. will post -3.53 earnings per share for the current year.
Insider Buying and Selling at Relmada Therapeutics
Institutional Trading of Relmada Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of RLMD. Stratos Wealth Partners LTD. bought a new position in shares of Relmada Therapeutics during the third quarter worth about $48,000. TD Asset Management Inc raised its stake in shares of Relmada Therapeutics by 100.0% during the 3rd quarter. TD Asset Management Inc now owns 25,000 shares of the company’s stock worth $75,000 after purchasing an additional 12,500 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Relmada Therapeutics during the fourth quarter worth $243,000. Silverarc Capital Management LLC acquired a new stake in Relmada Therapeutics in the third quarter valued at $300,000. Finally, Vestal Point Capital LP bought a new position in shares of Relmada Therapeutics in the 4th quarter valued at about $476,000. Institutional investors and hedge funds own 45.24% of the company’s stock.
About Relmada Therapeutics
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.
Read More
- Five stocks we like better than Relmada Therapeutics
- 3 Warren Buffett Stocks to Buy Now
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- P/E Ratio Calculation: How to Assess Stocks
- Merger or Not, Albertson’s Companies is a Good Buy
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.